The rationale of systemic treatments with the bone-seeking calcium mimetic 223Radium-dichloride and PSMA-targeting radioligand 177Lutetium-PSMA-617 is the selective internal radiation of prostate cancer cells. Here, FOLH1 is linked to prostate cancer.